<DOC>
	<DOCNO>NCT02567331</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , pharmacoeconomics oral capecitabine patient metastatic colorectal cancer . The anticipated time study treatment 3-12 month , target sample size 28 individual .</brief_summary>
	<brief_title>A Study Capecitabine ( Xeloda ) Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adult patient great equal ( &gt; = ) 18 year age Metastatic colorectal cancer Previous cytotoxic chemotherapy immunotherapy advance metastatic disease Central nervous system bone metastases Moderate severe renal impairment Clinically significant cardiac disease Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability take oral medication Malignancy within last 5 year , except cure basal cell cancer skin cure cancer situ uterine cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>